Medical Cannabis Market Size Projected to Reach $40.48 Billion by 2032

Precedence Research

Precedence Research

The global medical cannabis market size was valued a USD 12.60 billion in 2023 and is projected to reach around USD 40.48 billion by 2032, with a double-digit CAGR of 13.8% between 2023 and 2032.

Ottawa, Feb. 23, 2024 (GLOBE NEWSWIRE) — The medical cannabis market size is estimated to be worth around USD 25.28 billion by 2029 from USD 13.79 billion in 2024, according to a study published by Towards Healthcare a sister firm of Precedence Research. North America reigns supreme, boasting a commanding 56% share, thanks to early legalization, established market, and booming popularity.

In 2023, according to the World Health Organization, it is estimated that around 50 million individuals are suffering from Epilepsy in the United States and showing a greater risk of premature death due to epilepsy. Medical cannabis hits high notes for Epilepsy, Chronic Pain Management and Rare Diseases.

Download a short version of this report @

Medical cannabis is obtained from the Cannabis Sativa plant and has been used for centuries due to its potential therapeutic benefits. Cannabis contains two main active compounds: Tetrahydrocannabinol (THC) and Cannabidiol (CBD). THC is known for its psychoactive properties, whereas CBD is non-psychoactive and has a variety of health benefits. The human body contains an endocannabinoid system (ECS), which regulates various physiological processes. Cannabinoids found in medical cannabis interact with receptors in the ECS, influencing processes such as pain perception, immunity and mood. One of the primary applications of medical cannabis is pain relief and it is used for various symptoms and diseases. THC can help alleviate chronic pain by altering how pain signals are processed in the brain. CBD, on the other hand, may have anti-inflammatory and analgesic properties without causing the “high” associated with THC. Medical cannabis is also utilized to manage nausea and vomiting, often in patients undergoing chemotherapy. THC can help reduce these symptoms and improve the quality of life for individuals undergoing cancer treatments.

In some cases, medical cannabis is prescribed for muscle spasms and spasticity associated with conditions like multiple sclerosis. The cannabinoids’ muscle-relaxant properties may provide relief for these symptoms. It’s crucial to highlight that the legal status of medical cannabis varies widely around the world and even within different regions of a country. Some places have legalized its use for medicinal purposes, while others still have strict regulations or complete prohibition. Before considering medical cannabis, individuals should consult with healthcare professionals to discuss potential benefits, risks and legal implications based on their specific health conditions and local regulations.

Medical Cannabis Market Analysis Survey, 2022

The DHHS center for medical cannabis surveyed participants in the state’s medical cannabis program. The survey aimed to gather feedback on the state’s medical cannabis sector regarding product access availability.

Additionally, medical cannabis, also known as medical marijuana, utilizes either the cannabis plant or its chemical components to address symptoms or medical conditions. While medical marijuana is available in forms similar to recreational use, there are also refined lab-made versions for specific health issues. Historically, cannabis use traces back to Central Asia or Western China, with documented instances dating back to 2800 BC in Emperor Shen Nung’s pharmacopeia. The cannabis plant contains over 100 cannabinoids, with THC and CBD being the primary ones used in medicine. THC induces the characteristic “high”, whether through smoking or ingesting cannabis-infused products. As of 2023, medical marijuana products were legally accessible in 38 states, three territories and the District of Columbia despite remaining prohibited under federal law.

You can place an order or ask any questions, please feel free to contact us at

The Role of Medical Cannabis in Treating Various Symptoms and Conditions

In states where medical marijuana is sanctioned, its approval extends to a diverse range of medical conditions, such as

  • Severe and Persistent Pain

  • Multiple Sclerosis

  • Chemotherapy-Induced Nausea

  • Epilepsy

  • Alzheimer’s

  • ALS


  • Crohn’s Disease

  • Glaucoma

  • Migraines

  • Anorexia

  • Wasting Syndrome

  • Irritable Bowel Syndrome

  • Post-Traumatic Stress Disorder

It’s imperative to recognize that some endorsed applications lack robust scientific validation. This discrepancy arises, in part, from the challenge researchers face in conducting comprehensive studies on a substance that, despite state-level approval, remains federally prohibited. The intricacies of this legal landscape contribute to limitations in establishing conclusive evidence for certain medicinal uses of Cannabis. More and more folks are realizing the amazing health benefits of medical cannabis, and it’s causing a big demand boost in the market. People are getting hip to the therapeutic perks of cannabis-based products and as we all get more comfortable with using cannabis for medical reasons, the demand is shooting up. Ongoing research backing up its effectiveness also plays a role, making these products even more popular. It’s like everyone’s realizing that cannabis is a legitimate and valuable part of taking care of our health.

A cannabis patient cardholder is someone whose state’s regulatory body has issued a medical marijuana card or license. This card verifies that the holder has a qualifying medical condition that makes them eligible to use cannabis for therapeutic purposes.

Prescription Drugs Based on Cannabis Compounds

The FDA hasn’t endorsed marijuana for health issues, but it has given the thumbs up to two prescription medications featuring synthetic cannabinoids.

FDA-Approved Medical Cannabis Drugs:

  • Dronabinol, also known as Marinol, comes into play for managing chemotherapy-induced nausea and vomiting and addressing appetite and weight loss in individuals with HIV/AIDS.

  • Nabilone, marketed as Cesamet, steps in to alleviate nausea and vomiting from chemotherapy when other remedies fall short.

What sets these drugs apart from medical marijuana is the ability to regulate the active ingredient precisely, ensuring a consistent and known dosage each time. This level of control contributes to a more reliable and predictable therapeutic experience.

Cannabis has Potential Benefits in Managing Epilepsy

Epilepsy is a persistent neurological condition affecting individuals across all age groups. Globally, approximately 50 million people grapple with epilepsy, marking it as one of the most prevalent neurological disorders. Alarmingly, around 80% of those affected reside in low and middle income nations. With proper diagnosis and treatment, up to 70% of individuals living with epilepsy could potentially lead seizure-free lives. Unfortunately, the risk of premature death is three times higher in people with epilepsy compared to the general population. Regrettably, a significant number of individuals in low-income countries, around three-quarters, lack access to the necessary treatment. Beyond the medical challenges, many regions worldwide witness people with epilepsy and their families enduring the burden of societal stigma and discrimination. Addressing these issues requires a concerted effort to enhance accessibility to proper care and eliminate misconceptions surrounding epilepsy. Research suggests that certain compounds in cannabis, such as Cannabidiol (CBD), may have anticonvulsant properties and could potentially help manage epilepsy. CBD interacts with the endocannabinoid system in the body, influencing neural activity. However, it’s crucial to consult with a healthcare professional before considering any cannabis-related treatment for epilepsy, as the effectiveness and safety can vary and individual responses may differ.

While some studies suggest that certain compounds in cannabis, particularly cannabidiol (CBD), may have anticonvulsant properties, the overall evidence supporting cannabis as a primary treatment for epilepsy is not yet conclusive.

For Instance,

  • Epidiolex, a CBD-based medication, has been approved by the U.S. Food and Drug Administration (FDA) for specific types of seizures associated with epilepsy. Cannabis is gaining recognition for its role in epilepsy treatment, with an increasing demand for its medicinal use.

  • In 2023, according to the World Health Organization, around 50 million individuals in the United States are affected by epilepsy, comprising 3 million adults and 470,000 children. Notably, epilepsy stands out as one of the leading causes of hospital inpatient stays among children aged 0 to 17 in the U.S.

Many individuals are finding relief through cannabis-based therapies, and as awareness grows, so does the demand for these medicinal products. This positive shift reflects a changing perspective on the potential benefits of cannabis in managing epilepsy, providing hope for those seeking alternative, effective treatments and increasing demand for medical cannabis in the market.

Medical Cannabis Faces a Tangled Web of Legal and Regulatory Hurdles

The challenge of legal and regulatory issues in the medical cannabis market is like facing a tricky obstacle course. Imagine each country having its own set of rules – some straightforward, others complex. The first hurdle is the patchwork of regulations globally; what’s legal in one place might be strictly prohibited in another. The clash of rules between regions adds complexity, creating a regulatory puzzle. It’s like trying to follow a map with conflicting instructions, making the journey more challenging. Concerns about misuse and safety act as barriers. Some fear that opening the doors to medical cannabis could lead to problems. This concern adds an extra layer of difficulty, making the regulatory landscape akin to a…

Read More: Medical Cannabis Market Size Projected to Reach $40.48 Billion by 2032

2024-02-23 16:00:00

Notify of
Inline Feedbacks
View all comments